Study of REGN2810 (Anti-PD-1) in Patients With Advanced Malignancies

PHASE1CompletedINTERVENTIONAL
Enrollment

398

Participants

Timeline

Start Date

February 2, 2015

Primary Completion Date

November 18, 2019

Study Completion Date

November 18, 2019

Conditions
Advanced CancerAdvanced Malignancies
Interventions
DRUG

Cemiplimab

RADIATION

Hypofractionated radiotherapy

DRUG

Cyclophosphamide

DRUG

Docetaxel

DRUG

Carboplatin

DRUG

GM-CSF

DRUG

Paclitaxel

DRUG

Pemetrexed

Trial Locations (47)

15232

University of Pittsburgh Medical Center Shadyside, Pittsburgh

90025

The Angeles Clinic and Research Institute, Los Angeles

Unknown

Banner MD Anderson Cancer Center, Gilbert

Western Regional Medical Center, Goodyear

Mayo Clinic, Phoenix

University of Arizona Cancer Center, Tucson

City of Hope National Medical Center, Duarte

Ronald Reagan UCLA Medical Center, Los Angeles

Stanford University, Stanford

Sarah Cannon Research Institute at HealthONE, Denver

Norwalk Hospital, Norwalk

Georgetown University Medical Center, Washington D.C.

H Lee Moffitt Cancer Center and Research Institute, Tampa

Winship Cancer Institute, Emory University, Atlanta

University of Chicago, Chicago

Indiana University, Indianapolis

University of Kansas Cancer Center, Fairway

Dana Farber Cancer Institute, Boston

Barbara Ann Karmanos Cancer Center, Detroit

Washington University School of Medicine Siteman Cancer Center, St Louis

Nebraska Methodist Hospital, Omaha

Hackensack University Medical Center, Hackensack

Cancer Institute of New Jersey, New Brunswick

Columbia University Medical Center, New York

Laura & Isaac Perlmutter Cancer Center, New York

Mount Sinai Medical Center, New York

Weill Cornell Medical College, New York

Duke Cancer Institute, Durham

University Hospitals Case Medical Center, Cleveland

Stephenson Cancer Center, Oklahoma City

Providence Portland Medical Center, Portland

Penn State Milton S Hershey Medical Center, Hershey

Miriam Hospital, Providence

Sarah Cannon Research Institute, Nashville

Vanderbilt University Medical Center, Nashville

Mary Crowley Cancer Research Center - Medical City, Dallas

Baylor College of Medicine, Houston

The University of Texas MD Anderson Cancer Center, Houston

START South Texas Accelerated Research Therapeutics, San Antonio

Northwest Medical Specialties, Tacoma

Peter Maccallum Cancer Centre, Melbourne

Institut Catala d'Oncologia L'hospitalet, L'Hospitalet de Llobregat

Hospital Universitario Vall d'Hebron, Barcelona

Fundacion Jimenez Diaz, Madrid

Hospital Universitario HM Sanchinarro-CIOCC, Madrid

Hospital Universitario Ramon y Cajal, Madrid

MD Anderson Cancer Center, Madrid

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Sanofi

INDUSTRY

lead

Regeneron Pharmaceuticals

INDUSTRY